This article will be freely available to view in February 2022. Labiotech members have exclusive access before it is unlocked.
December 2021 ended with a bang for biotech funding in Europe and Israel, with cultured meat and cell therapy startups attracting the biggest investment rounds.
Biotech companies in Europe and Israel capped off 2021 with a very strong month of fundraising. Collectively, private companies and those launching initial public offerings (IPOs) banked almost €1.6B in 43 biotech investment deals.
The December total was roughly 30% larger than November’s haul of €1.2B. Only €58M of December’s winnings came from biotech IPOs, in contrast to the €515M collected from biotech IPOs in November.
Genenta Science launched the biggest European biotech IPO of December, raising almost €32M on the Nasdaq. The Italian firm is developing a gene therapy that penetrates solid tumors and produces proteins activating the immune system against the cancer cells.
In second place,